Pathogenic myeloid phenotypes drive disease pathology in a novel human neurohistiocytosis model

Read full text
Authors: Shivakumar Rajamanickam, Samantha Trescott, Sht Mak, Anna S. Warden, Amanda M Wilpitz, Bing Xia, Celina T. Nguyen, Hilda Ding, Jennifer Lee Picarsic, Christopher K. Glass, Carl E. Allen, Nicole G. Coufal
Cited by: 1
References: 85

Abstract

ABSTRACT: Innate immunity is increasingly recognized as a driver of neurodegeneration, although pathogenic mechanisms are incompletely understood. Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplastic disorder caused by activating somatic mutations in MAPK pathway genes, most commonly BRAFV600E, in myeloid precursors. A subset of patients with LCH develop progressive neurodegeneration (LCH-ND). We generated a human induced pluripotent stem cell (iPSC) model from patients with somatic hematologic mosaicism for BRAFV600E. Brain macrophages/microglia from LCH iPSCs exhibit unique disease-specific pathogenic features. Stepwise differentiation identified hematopoietic progenitors as hyperproliferative, whereas brain macrophages were apoptosis resistant. Through application of cerebral organoids and a humanized murine xenotransplantation model, we identify marked heterogeneity of differentiation potential within clonal BRAFV600E lines in vivo. This model phenocopied human-specific phenotypes, including dense basal ganglia foci of abnormal macrophages, marked neurodegeneration with astrogliosis, and progressive ataxia. This approach will allow for preclinical testing of therapeutics for LCH-ND.

Fields of Study & Subjects

Histiocytic Disorders and Treatments CNS Lymphoma Diagnosis and Treatment Autoimmune and Inflammatory Disorders Research

Publication details

Journal / source
Blood
Publisher
American Society of Hematology
Volume
148
Issue
4
Pages
433–449
Publication date
31 March 2026
Language
EN